-

GE HealthCare unveils enhanced Voluson Expert Series women’s health ultrasound systems with focus on early detection and exam efficiency

  • Latest Voluson Expert 22, 20 and 18 ultrasound systems harness artificial intelligence and advanced tools and software for more efficient assessments
  • Voluson Expert Series delivers elevated performance, with focus on first trimester to reveal clearer anatomical details, aiding earlier detection and boosting diagnostic confidence

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and a world-class user experience. The Voluson Expert Series integrates artificial intelligence (AI)-powered features and automation tools to help drive imaging performance and efficiencies in women’s healthcare.

Approximately 30,000 to 50,000 women in the United States experience complex, high-risk pregnancy each year.i When these complications are left undetected or untreated, it may harm the mother or the baby. The growing prevalence of these complicationsii underscores the need for innovative solutions that enable early detection and intervention.

The Voluson Expert Series, GE HealthCare’s most advanced women’s health ultrasound systems, offers premium ultrasound imaging for confident diagnoses for high risk, complex pregnancies. The Lyric Architecture is designed to unlock new imaging and processing power to deliver detailed and uniform images and reveal finer details within the anatomy with ease, even in difficult scanning conditions. AI-enabled functionality and automation tools are available to support faster assessments and early detection, diagnosis and intervention.

The SonoLyst suite of AI tools were designed to simplify exams through image recognition and automated annotations and measurements, increasing exam speed and accuracy. With this new release, clinicians can now utilize SonoLystlive during 11 to 14-week anatomical exams helping ensure required views are captured for diagnostic accuracy.  In addition, Voluson Expert Series ultrasound systems feature an expanded color Doppler offering, Graphicflow, which provides a graphical representation of the trajectories of the blood cells in real-time to visualize complex blood flow quickly and clearly, helping users differentiate normal from abnormal hemodynamics.

Voluson Expert Series also includes additional enhancements to select Voluson AI tools:

  • SonoPelvicFloor3.0 can help reduce pelvic floor measurement exam time by 80%.* This feature now expands anatomical views, and simplifies the exam process by automating plane alignment, live C-plane tracking, and measurements.
  • SonoAVCfollicle2.0 uses AI to increase accuracy and precision in follicle detection, resulting in a better success rate of detecting follicles, along with reduced artifacts and requiring less time for postprocessing.

These systems are compatible with a wide selection of unique specialty probes, including a new lightweight 2D/3D probe RAB7-D, and wireless Vscan Air™ dual probes.

“We are proud to introduce these updates to the Voluson Expert ultrasound systems, which represent our ongoing commitment to advancing technology that addresses women's health needs of today, and the future,” said Gerald Seifriedsberger, General Manager, Women’s Health, Advanced Visualization Solutions, GE HealthCare. “By introducing solutions that offer unparalleled clarity and detail, we can empower users with critical insights for informed care decisions and efficient exams, transforming how clinicians approach healthcare. Together, we can create a healthier future for all women.”

GE HealthCare will showcase the Voluson Expert series ultrasound systems at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting™ taking place on January 27-February 1 in Denver. The Voluson Expert Series is available in the United States. For more information on the Voluson Expert Series, visit: https://www.gehealthcare.com/products/ultrasound/voluson.

*Versus manual exam

___________________________________

i Cleveland Clinic. High-Risk Pregnancy. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22190-high-risk-pregnancy. Last reviewed July 12, 2024. Accessed January 17, 2025.

ii Barfield WD, Besera G, Cox S, Warner L, Azeez O, Riggs J, Russell R, Bowron S, Churchill RE. From Data to Action: CDC's Public Health Surveillance for Women, Infants, and Children. 2nd ed. Centers for Disease Control and Prevention; 2020. https://www.cdc.gov/reproductive-health/media/pdfs/data-to-action/Data-To-Action_508.pdf. Accessed January 17, 2025.

 

Contacts

Eric Tatro
Media Contact
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

GE HealthCare

NASDAQ:GEHC

Release Versions

Contacts

Eric Tatro
Media Contact
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

More News From GE HealthCare

GE HealthCare to announce second quarter 2025 results on July 30, 2025

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will...

GE HealthCare announces cash dividend for second quarter of 2025

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled sol...

GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025

CHICAGO--(BUSINESS WIRE)--GE HealthCare’s commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. As cardiovascular disease (CVD) continues to rise globally,i the need for advanced diagnostic technologies becomes increasingly critical. GE HealthCare's molecular imaging technologies – including positron emission tomograp...
Back to Newsroom